The role of reverse genetics systems in studying viral hemorrhagic fevers

Thrombosis and Haemostasis

Volumn 94, Issue 2, 2005, Pages 240-253

  Ebihara, Hideki ^a,e,f   Groseth, Allison ^b,c   Neumann, Gabriele ^d   Kawaoka, Yoshihiro ^a,d,e   Feldmann, Heinz ^b,c,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f NONE   (Canada)

Author keywords

Pathogenesis; Reverse genetic systems; Viral hemorrhagic fever

Indexed keywords

ANTIVIRUS AGENT; CANDID 1; COMPLEMENTARY DNA; GLYCOPROTEIN; HANTAVAX; VIRUS VACCINE;

DRUG SYNTHESIS; FATALITY; GENETIC ANALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; MOLECULAR CLONING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPLICON; REVIEW; RNA VIRUS; TAXONOMY; VIRUS HEMORRHAGIC FEVER; VIRUS MUTANT; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ARENAVIRIDAE; BUNYAVIRIDAE; DNA, COMPLEMENTARY; DNA, VIRAL; FILOVIRIDAE; FLAVIVIRIDAE; GENES, VIRAL; GENETIC TECHNIQUES; GENOME, VIRAL; HEMORRHAGIC FEVERS, VIRAL; HUMANS; MODELS, BIOLOGICAL; MUTATION; RNA, VIRAL;

EID: 23744512867     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-05-0335     Document Type: Review

References (137)

1. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004; 10: S110-21.
2. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1: 11-20.
3. Nichol ST. In: Bunyaviruses. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Lippincott Williams & Wilkins, Philadelphia 2001 1603-33.
4. Peters CJ, Buchmeier MJ, Rollin PE, Ksiazek TG. In: Arenaviruses. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE. Lippincott Williams & Wilkins, Philadelphia 1996: 1521-52.
5. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek, TG, Peters CJ. In: Filoviridae: Marburg and Ebola Viruses. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Lippincott Williams & Wilkins, Philadelphia 2001: 1279-304.
6. Schnittler HJ, Feldmann H. Viral hemorrhagic fever - a vascular disease? Thromb Haemost 2003; 89: 967-72.
7. Charrel RN, de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res 2003; 57: 89-100.
8. Borio L, Inglesby T, Peters CJ et al. Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391-405.
9. Conzelmann KK. Reverse genetics of mononegavirales. Curr Top Microbiol Immunol 2004; 283: 1-41.
10. Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? J Gen Virol 2002; 83: 2635-62.
11. Kanerva M, Mustonen J, Vaheri A. Pathogenesis of puumala and other hantavirus infections. Rev Med Virol 1998; 8: 67-86.
12. Zaki SR, Greer PW, Coffield LM et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146: 552-79.
13. Ambrosio M, Vallejos A, Saavedra C et al. Junin virus replication in peripheral blood mononuclear cells of patients with Argentine haemorrhagic fever. Acta Virol 1990; 34: 58-63.
14. Baize S, Kaplon J, Faure C et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 2004; 172: 2861-9.
15. Bosio CM, Aman MJ, Grogan C et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003; 188: 1630-8.
16. Geisbert TW, Young HA, Jahrling PB et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163: 2371-82.
17. Geisbert TW, Hensley LE, Larsen T et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163: 2347-70.
18. Raftery MJ, Kraus AA, Ulrich R et al. Hantavirus infection of dendritic cells. J Virol 2002; 76: 10724-33.
19. Wu SJ, Grouard-Vogel G, Sun W et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6: 816-20.
20. Carr JM, Hocking H, Bunting K et al. Supernatants from dengue virus type-2 infected macrophages induce permeability changes in endothelial cell monolayers. J Med Virol 2003; 69: 521-8.
21. Feldmann H, Bugany H, Mahner F et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996; 70: 2208-14.
22. Geisbert TW, Young HA, Jahrling PH et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188: 1618-29.
23. Schnittler HJ, Feldmann H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr Top Microbiol Immunol 1999; 235: 175-204.
24. Ströher U, West E, Bugany H et al. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001; 75: 11025-33.
25. Wahl-Jensen V, Kurz SK, Hazelton PR et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005; 79: 2413-9.
26. Heller MV, Saavedra MC, Falcoff R et al. Increased tumor necrosis factor-alpha levels in Argentine hemorrhagic fever. J Infect Dis 1992; 166: 1203-4.
27. Mahanty S, Bausch DG, Thomas RL et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 2001; 183: 1713-21.
28. Marta RF, Montero VS, Hack CE et al. Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hyg 1999; 60: 85-9.
29. Geisbert TW, Hensley LE, Gibb TR et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80: 171-86.
30. Hensley LE, Young HA, Jahrling PB et al. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80: 169-79.
31. Mahanty S, Hutchinson K, Agarwal S et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170: 2797-801.
32. Gavrilovskaya IN, Peresleni T, Geimonen E et al. Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration. Arch Virol 2002; 147: 1913-31.
33. Lei HY, Yeh TM, Liu HS et al. Immunopathogenesis of dengue virus infection. J Biomed Sci 2001; 8: 377-88.
34. Lin CF, Lei HY, Shiau AL et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol 2002; 169: 657-64.
35. Lin CF, Lei HY, Shiau AL et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 2003; 69: 82-90.
36. Walker DH, McCormick JB, Johnson KM et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 1982; 107: 349-56.
37. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr Top Microbiol Immunol 2002; 262: 75-109.
38. Gritsun TS, Nuttall P A, Gould E A. Tick-borne flaviviruses. Adv Virus Res 2003; 61: 317-71.
39. Bowen MD, Trappier SG, Sanchez AJ et al. A reassortant bunyavirus isolated from acute hemorrhagic fever cases in Kenya and Somalia. Virology 2001; 291: 185-90.
40. Gerrard SR, Li L, Barrett AD et al. Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol 2004; 78: 8922-6.
41. Buchmeier MJ, Bowen MD, Peters CJ. In: Arenaviridae: The viruses and their replication. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Lippincott Williams & Wilkins, Philadelphia. 2001: 1635-68.
42. Lindenbach BD, Rice CM. In: Flaviviridae: the virus and their replication. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE. Lippincott Williams & Wilkins Philadelphia 2001: 991-1042.
43. Schmaljohn CS, Hooper JW. In: Bunyaviridae: The viruses and their replication. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Lippincott Williams & Wilkins, Philadelphia 2001: 1581-602.
44. Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981; 214: 916-9.
45. Ruggli N, Rice CM. Functional cDNA clones of the Flaviviridae: strategies and applications. Adv Virus Res 1999; 53: 183-207.
46. Luytjes W, Krystal M, Enami M et al. Amplification, expression, and packaging of foreign gene by influenza virus.Cell 1989; 59: 1107-13.
47. Enami M, Luytjes W, Krystal M et al. Introduction of site-specific mutations into the genome of influenza virus Proc Natl Acad Sci U S A 1990; 87: 3802-5.
48. Fuerst TR, Niles EG, Studier FW et al. Ekaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A 1986; 83: 8122-6.
49. Pattnaik AK, Ball LA, LeGrone AW et al. Infectious defective interfering particles of VSV from transcripts of a cDNA clone. Cell 1992; 69: 1011-20.
50. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. Embo J 1994; 13: 4195-203.
51. Bridgen A, Elliott RM. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proc Natl Acad Sci U S A 1996; 93: 15400-4.
52. Lindenbach BD, Rice CM. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication. J Virol 1997; 71: 9608-17.
53. Jones CT, Patkar CG, Kuhn RJ. Construction and applications of yellow fever virus replicons. Virology 2005; 331: 247-59.
54. Pang X, Zhang M, Dayton AI. Development of Dengue virus type 2 replicons capable of prolonged expression in host cells. Bmc Microbiol 2001; 1: 18.
55. Lopez N, Muller R, Prehaud C, Bouloy M. The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules. J Virol 1995; 69: 3972-9.
56. Flick K, Hooper JW, Schmaljohn CS et al. Rescue of Hantaan virus minigenomes. Virology 2003; 306: 219-24.
57. Flick R, Flick K, Feldmann H et al. Reverse genetics for crimean-congo hemorrhagic fever virus. J Virol 2003; 77: 5997-6006.
58. Lee KJ, Novella IS, Teng MN et al. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol 2000; 74: 3470-7.
59. Lopez N, Jacamo R, et al. Transcription and RNA replication of tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes J Virol 2001; 75: 12241-51.
60. Hass M, Golnitz U, Muller S et al. Replicon system for Lassa virus. J Virol 2004; 78: 13793-803.
61. Cornu TI, de la Torre JC. Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol 2002; 76: 6678-88.
62. Muhlberger E, Lotfering B, Klenk HD et al. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J Virol 1998; 72: 8756-64.
63. Muhlberger E, Weik M, Volchkov VE et al. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 1999; 73: 2333-42.
64. Groseth A, Feldmann H, Theriault S et al. RNA polymerase I-driven minigenome system for Ebola viruses. J Virol 2005; 79: 4425-33.
65. Hoffmann E, Neumann G, Kawaoka Y et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97: 6108-13.
66. Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 1999; 96: 9345-50.
67. Theriault S, Groseth A, Neumann G et al. Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res 2004; 106: 43-50.
68. Watanabe S, Watanabe T, Noda T et al. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol 2004; 78: 999-1005.
69. Noda T, Sagara H, Suzuki E et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76: 4855-65.
70. Rice CM, Grakoui A, Galler R et al. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1989; 1: 285-96.
71. Lai CJ, Zhao BT, Hori H et al. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A 1991; 88: 5139-43.
72. Tesh RB, Guzman H, da Rosa AP et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 2001; 183: 1431-6.
73. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle et al. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 2003; 100: 14333-8.
74. Leitmeyer KC, Vaughn DW, Watts DM et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 73: 4738-47.
75. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003; 77: 3929-38.
76. Pryor MJ, Carr JM, Hocking H et al. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 2001; 65: 427-34.
77. Neumann G, Feldmann H, Watanabe S et al. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 2002; 76: 406-10.
78. Volchkov VE, Volchkova VA, Muhlberger E et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291: 1965-9.
79. Towner JS, Paragas J, Dover JE et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 2005; 332: 20-7.
80. Hoenen T, Volchkov V, Kolesnikova L et al. VP40 octamers are essential for Ebola virus replication. J Virol 2005; 79: 1898-905.
81. Bray M, Davis K, Geisbert T et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999; 179: S248-58.
82. Volchkov VE, Chepurnov AA, Volchkova VA et al. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000; 277: 147-55.
83. Connolly BM, Steele KE, Davis KJ et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179 Suppl 1: S203-17.
84. Feldmann H, Volchkov VE, Volchkova VA et al. Biosynthesis and role of filoviral glycoproteins. J Gen Virol 2001; 82: 2839-48.
85. Ito H, Watanabe S, Sanchez A et al. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol 1999; 73: 8907-12.
86. Ito H, Watanabe S, Takada A et al. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 2001; 75: 1576-80.
87. Takada A, Watanabe S, Ito H et al. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 2000; 278: 20-6.
88. Takada A, Watanabe S, Okazaki K et al. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol 2001; 75: 2324-30.
89. Watanabe S, Takada A, Watanabe T et al. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 2000; 74: 10194-201.
90. Sanchez A, Trappier SG, Mahy BW, et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996; 93: 3602-7.
91. Volchkov VE, Becker S, Volchkova VA et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995; 214: 421-30.
92. Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002; 303: 9-14.
93. Yang Z, Delgado R, Xu L et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998; 279: 1034-7.
94. Barrientos LG, Martin AM, Rollin PE et al. Disulfide bond assignment of the Ebola virus secreted glycoprotein SGP. Biochem Biophys Res Commun 2004; 323: 696-702.
95. Volchkov VE, Feldmann H, Volchkova VA et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 1998; 95: 5762-7.
96. Nagai Y, Klenk HD. Activation of precursors to both glycoporteins of Newcastle disease virus by proteolytic cleavage. Virology 1977; 77: 125-34.
97. Rott R. Genetic determinants for infectivity and pathogenicity of influenza viruses. Philos Trans R Soc Lond B Biol Sci 1980; 288: 393-9.
98. Peeters BP, de Leeuw OS, Koch G et al. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999; 73: 5001-9.
99. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994; 68: 3120-8.
100. Simmons G, Wool-Lewis RJ, Baribaud F et al. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 2002; 76: 2518-28.
101. Takada A, Fujioka K, Tsuiji M et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 2004; 78: 2943-7.
102. Sanchez AJ, Vincent MJ, Nichol ST. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol 2002; 76: 7263-75.
103. Alvarez CP, Lasala F, Carrillo J et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002; 76: 6841-4.
104. Geijtenbeek TB, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003; 197: 7-17.
105. Ludwig IS, Lekkerkerker AN, Depla E et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol 2004; 78: 8322-32.
106. Volchkov VE, Blinov VM, Netesov SV. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett 1992; 305: 181-4.
107. Ignatyev GM. Immune response to filovirus infections. Curr Top Microbiol Immunol 1999; 235: 205-17.
108. Ahr B, Robert-Hebmann V, Devaux C et al. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 2004; 1: 12.
109. Schecter AD, Berman AB, Yi L et al. HIV envelope gp120 activates human arterial smooth muscle cells Proc Natl Acad Sci U S A 2001; 98: 10142-7.
110. Takada A, Feldmann H, Ksiazek TG et al. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77: 7539-44.
111. Basler CF, Palse P. Modulation of Innate Immunity by Filoviruses. In: Ebola and Marburg Viruses: Molecular and Cellular Biology. Klenk HD, Feldmann H, ed. Horizon bioscience, Norfolk 2004.
112. Basler CF, Wang X, Muhlberger E et al. The Ebola virus VP35 protein functions as a type I IFN antagonist Proc Natl Acad Sci U S A 2000; 97: 12289-94.
113. Basler CF, Mikulasova A, Martinez-Sobrido L et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77: 7945-56.
114. Hartman AL, Towner JS, Nichol ST. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004; 328: 177-84.
115. Huang Y, Xu L, Sun Y et al. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 2002; 10: 307-16.
116. Hart MK. Vaccine research efforts for filoviruses. Int J Parasitol 2003; 33: 583-95.
117. Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection J Gen Virol 2001; 82: 1365-73.
118. Ryabchikova E, Kolesnikova L, Smolina M et al. Ebola virus infection in guineapigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol 1996; 141: 909-21.
119. Chepurnov AA, Zubavichene NM, Dadaeva AA. Elaboration of laboratory strains of Ebola virus and study of pathophysiological reactions of animals inoculated with these strains. Acta Trop 2003; 87: 321-9.
120. Plyusnin A, Kukkonen SK, Plyusnina A et al. Transfection-mediated generation of functionally competent Tula hantavirus with recombinant S RNA segment. Embo J 2002; 21: 1497-503.
121. Maes P, Clement J, Gavrilovskaya I et al. Hantaviruses: immunology, treatment, and prevention Viral Immunol 2004; 17: 481-97.
122. Hevey M, Negley D, Pushko P et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251: 28-37.
123. Pushko P, Geisbert J, Parker M et al. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001; 75: 11677-85.
124. Geisbert TW, Pushko P, Anderson et al. Evaluation in nonhuman primates of vaccines against Ebola virus Emerg Infect Dis 2002; 8: 503-7.
125. Rose JK, Whitt MA. In: Rhabdoviridae: The viruses and their replication. Knipe DM, Howley PM, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Lippincott Williams & Wilkins, Philadelphia 2001: 1221-44.
126. Whelan SP, Ball LA, Barr JN et al. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 1995; 92: 8388-92.
127. Lawson ND, Stillman EA, Whitt MA et al. Recombinant vesicular stomatitis viruses from DNA Proc Natl Acad Sci U S A 1995; 92: 4477-81.
128. Schnell MJ, Buonocore L, Kretzschmar E et al. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles Proc Natl Acad Sci U S A 1996; 93: 11359-65.
129. Buonocore L, Blight KJ, Rice CM et al. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002; 76: 6865-72.
130. Haglund K, Forman J, Krausslich HG et al. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 2000; 268: 112-21.
131. Kahn JS, Schnell MJ, Buonocore L et al. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 1999; 254: 81-91.
132. Takada A, Robison C, Goto H et al. A system for functional analysis of Ebola virus glycoprotein Proc Natl Acad Sci U S A 1997; 94: 14764-9.
133. Ogino M, Ebihara H, Lee BH et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virusenvelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol 2003; 10: 154-60.
134. Takada A, Feldmann H, Strocher U et al. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 2003; 77: 1069-74.
135. Garbutt M, Liebscher R, Wahl-Jensen V et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78: 5458-65.
136. Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine platform protects non-human primates against lethal challenge with either Ebola virus or Marburg virus. Nature Med 2005; in press.
137. Geisbert TW, Jones S, Fritz EA et al. Development of a new accelerated vaccine for the prevention of Lassa fever. PLoS 2005: in press.